Global Cancer Immunotherapy Market
The global cancer immunotherapy market is estimated to be worth over USD345.19Bn in 2033 and is expected to grow at CAGR of 12.5 % during the forecast period (2024-2033).
The global cancer immunotherapy market is witnessingstrong growth, fuelled by the growing prevalence of cancer, developments in biotechnology, and escalated awareness of immunotherapy’s potential. Immunotherapy, which harnesses the body’s immune system to target and destroy cancer cells, exhibits a revolutionarymove in oncology. Traditional cancer treatments often have majoradverse effects and limited efficiency, whereas immunotherapy provides more targeted and potentially long-lasting solutions. This transition is accelerated by major developments such as the approval and widespread use of checkpoint inhibitors like pembrolizumab and nivolumab, which have illustratedsignificantefficiency in treating different cancers including melanoma and lung cancer.
Another noteworthy advancement is CAR-T cell therapy, exemplified by treatments like Kymriah and Yescarta. These therapies comprise modifying a patient’s T-cells to better determine and combat cancer cells, displayingexceptional success in treating blood cancers. In addition to that, the development of personalized cancer vaccines and oncolytic virus therapies is further diversifying the arsenal of immunotherapeutic options, offering promising novel ways to improve the immune response against cancer.
Major driving factors for the market comprise the growing incidence of cancer worldwide, which surges the demand for effective treatments. The increased cost of conventional cancer therapies and their relatedadverse effects further push the need for more innovative and less toxic alternatives. Technological developments, specifically in genetic and molecular profiling, promote the trend towards precision medicine, allowing more personalized and effective treatment regimens.
The market also offers significant opportunities through the soaring trend towards combination therapies. By combining immunotherapy with other treatment modalities, such as chemotherapy or radiation, or with other immunotherapeutic agents, researchers can improve treatment efficiency and conquer resistance mechanisms. This trend is facilitated by continuous clinical trials and growing regulatory support, which are propelling the development and approval of new combination treatments.
Furthermore, the incorporation of artificial intelligence and big data analytics into cancer research is transforming the field, allowing the discovery of new biomarkers and the optimization of treatment plans. As a result, the global cancer immunotherapy market stands ready for sustained growth, fuelled by strategic partnerships, technological innovations, and an growing focus on personalized medicine. This dynamic panorama offers significant opportunities for enhancing patient outcomes and advancing cancer treatment.
The market report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this industry, across different geographies. Amongst other elements, the market report includes:
A preface providing an introduction to the full report, Cancer Immunotherapy market, 2023-2033.
An outline of the systematic research methodology adopted to conduct the study on Cancer Immunotherapy market, providing insights on the various assumptions, methodologies, and quality control measures employed to ensure accuracy and reliability of our findings.
An overview of economic factors that impact the overall Cancer Immunotherapy market, including historical trends, currency fluctuation, foreign exchange impact, recession, and inflation measurement.
An executive summary of the insights captured during our research, offering a high-level view of the current state of the Cancer Immunotherapy market and its likely evolution in the mid-to-long term.
A brief introduction to the Cancer Immunotherapy, highlighting their historical background, as well as information on their types, key aspects, key challenges and the advantages of using Cancer Immunotherapy.
A detailed assessment of the market landscape of Cancer Immunotherapy that are either approved or being evaluated in different stages of development, based on several relevant parameters, such as By Type (Monoclonal Antibodies, Cancer Vaccines, Checkpoint Inhibitors, Immunomodulators), By Application (Lung Cancer, Breast Cancer, Head & Neck Cancer, Prostate Cancer, Colorectal Cancer, Melanoma, Others), By End User (Hospitals, Clinics & Others). Further, the chapter features analysis on key niche market segments. In addition, the chapter features analysis of various Cancer Immunotherapy developers, based on their year of establishment, company size, location of headquarters and most active players.
An in-depth analysis of partnerships and collaborations that have been inked between various stakeholders, since 2019, based on several relevant parameters, such as the year of partnership, type of partnership, focus of partnership, purpose of partnership, therapeutic applications and most active players (in terms of number of partnerships). It also highlights the regional distribution of partnership activity in this market.
A detailed analysis of various investments made by companies engaged in this industry, since 2019, based on several relevant parameters, such as year of funding, type of funding (grants, seed, venture capital, initial public offering, secondary offerings, private equity and debt financing), type of HPAPIs, amount invested, geography, purpose of funding, stage of development, therapeutic area, most active players (in terms of number and amount of funding instances) and leading investors (in terms of number of funding instances).
An in-depth analysis of the various Cancer Immunotherapy focused initiatives undertaken by big market players, based on several relevant parameters, such as number of initiatives, year of initiative, type of initiative, purpose of initiative, focus of initiative and location of headquarters of the big pharma players.
One of the key objectives of this market report was to estimate the current market size and the future growth potential of the Cancer Immunotherapy over the forecast period. Based on several parameters, such as regional analysis as well as segmental analysis rates, we have developed informed estimates of the likely evolution of the Cancer Immunotherapy market over the forecast period 2023-2033. Our year-wise projections of the current and future opportunity have further been segmented based on relevant parameters, such as By Type (Monoclonal Antibodies, Cancer Vaccines, Checkpoint Inhibitors, Immunomodulators), By Application (Lung Cancer, Breast Cancer, Head & Neck Cancer, Prostate Cancer, Colorectal Cancer, Melanoma, Others), By End User (Hospitals, Clinics & Others), by key geographical regions (North America, Europe, Asia-Pacific, Middle East and Africa, and South America) and leading players. In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s evolution.